Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 19;6(1):35.
doi: 10.3390/biomedicines6010035.

VHL and Hypoxia Signaling: Beyond HIF in Cancer

Jing Zhang  1 , Qing Zhang  2   3
Affiliations
Review

VHL and Hypoxia Signaling: Beyond HIF in Cancer

Jing Zhang et al. Biomedicines. .

Abstract

Von Hippel-Lindau (VHL) is an important tumor suppressor that is lost in the majority of clear cell carcinoma of renal cancer (ccRCC). Its regulatory pathway involves the activity of E3 ligase, which targets hypoxia inducible factor α (including HIF1α and HIF2α) for proteasome degradation. In recent years, emerging literature suggests that VHL also possesses other HIF-independent functions. This review will focus on VHL-mediated signaling pathways involving the latest identified substrates/binding partners, including N-Myc downstream-regulated gene 3 (NDRG3), AKT, and G9a, etc., and their physiological roles in hypoxia signaling and cancer. We will also discuss the crosstalk between VHL and NF-κB signaling. Lastly, we will review the latest findings on targeting VHL signaling in cancer.

Keywords: Hypoxia; VHL; ccRCC.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic of multi-functionality of VHL in hypoxia signaling and cancer.
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 2016;66:7–30. doi: 10.3322/caac.21332. - DOI - PubMed
    1. Hsieh J.J., Purdue M.P., Signoretti S., Swanton C., Albiges L., Schmidinger M., Heng D.Y., Larkin J., Ficarra V. Renal cell carcinoma. Nat. Rev. Dis. Prim. 2017;3:17009. doi: 10.1038/nrdp.2017.9. - DOI - PMC - PubMed
    1. Choueiri T.K., Motzer R.J. Systemic therapy for metastatic renal-cell carcinoma. N. Engl. J. Med. 2017;376:354–366. doi: 10.1056/NEJMra1601333. - DOI - PubMed
    1. Moore L.E., Nickerson M.L., Brennan P., Toro J.R., Jaeger E., Rinsky J., Han S.S., Zaridze D., Matveev V., Janout V., et al. Von hippel-lindau (vhl) inactivation in sporadic clear cell renal cancer: Associations with germline vhl polymorphisms and etiologic risk factors. PLoS Genet. 2011;7:e1002312. doi: 10.1371/journal.pgen.1002312. - DOI - PMC - PubMed
    1. Nickerson M.L., Jaeger E., Shi Y., Durocher J.A., Mahurkar S., Zaridze D., Matveev V., Janout V., Kollarova H., Bencko V., et al. Improved identification of von hippel-lindau gene alterations in clear cell renal tumors. Clin. Cancer Res. 2008;14:4726–4734. doi: 10.1158/1078-0432.CCR-07-4921. - DOI - PMC - PubMed

LinkOut - more resources